In vivo, DNM1L overexpression increases subcutaneous tumor volume by −50% and markedly elevates hepatic metastatic nodules, whereas DNM1L knockdown reduces metastatic foci by at least half, identifying DNM1L as a key driver of GBC liver metastasis. Here, DNM1L is linked to neoplasm.